12:00 AM
Apr 16, 2012
 |  BioCentury  |  Strategy

GPCR gambit

Anaphore buys RuiYi for GPCR-targeting mAb platform and foothold in China

Although Anaphore Inc. has yet to enter the clinic with a program from its protein therapeutics platform, the company jumped at the opportunity to add a second biologics technology and thinks last month's stock acquisition of RuiYi Inc. will allow it to accomplish the difficult task of targeting GPCRs with mAbs.

Anaphore's TrimerX technology is based on tetranectin, a protein that contains five loops on each of its three plasminogen binding domains. By altering the amino acid sequence of the loops, the company can generate trivalent protein therapeutic analogs, dubbed Atrimers, which can bind a variety of targets(see BioCentury, Jan. 29, 2009).

President and CEO Paul Grayson said Anaphore is focused on developing Atrimers for inflammation and cancer. The inflammation program is partnered with Mitsubishi Tanabe Pharma Corp. under a 2010 deal and the most advanced molecule is at the affinity maturation stage, he said. The company has not disclosed...

Read the full 749 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >